Small-Cap REIT ETF ...
Health Care: Drugs
Endocyte Inc. (ECYT: NASDAQ)
$14.38 0.12 | 0.84%
05/17/13 - 04:00 PM ET
193.89K / 291.90K
Vol / Avg. Vol:14.35 / 14.26
Open / Prev. Close:14.05 - 14.50
Today's Range:6.01 - 15.36
52 Wk Range:58.80%
Performance YTD:TheStreet Rating:
Portfolios with ECYT
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- UserSmart Growth
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusal Vol...
- Contributor8 Health Care Stocks With R...
Latest ECYT Headlines from TheStreet
- Endocyte Appoints Scot L. Harper, Ph.D., As Vice President Of Clinical Operations 05.07.13 | 04:05 pm
- Endocyte Reports First Quarter 2013 Financial Results And Business Update 05.02.13 | 04:05 pm
- Clinical Study Shows Involvement Of Activated Macrophages In Osteoarthritis, Identified By Endocyte's Etarfolatide 04.25.13 | 05:04 pm
- Endocyte, Inc. Announces Annual Stockholders' Meeting 04.22.13 | 04:04 pm
- Endocyte Announces First Quarter 2013 Earnings Conference Call 04.18.13 | 04:04 pm
- Endocyte Announces Presentations At AACR Annual Meeting 2013 04.03.13 | 04:04 pm
- Endocyte To Present At The Future Leaders In The Biotech Industry Conference 04.01.13 | 08:04 am
- Endocyte To Webcast Investor And Analyst Day In New York City 03.18.13 | 09:03 am
- Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer And Non-Small Cell Lung Cancer Patients Most Likely To Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows 03.01.13 | 03:03 pm
- Endocyte To Present At Upcoming Conferences In March 02.26.13 | 04:02 pm
Press Releases for ECYT
- Merck And Endocyte Announce Acceptance For Review Of European Marketing Authorization Applications For Vintafolide And Companion Diagnostic Etarfolatide For Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Business Wire 11.27.12 | 08:11 am
- Merck And Endocyte Enter Exclusive Worldwide Agreement To Develop And Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Business Wire 04.16.12 | 07:04 am
Partner Headlines for ECYT
- Company News for April 17, 2012 - Corporate Summary - Zacks 04.17.12 | 10:04 am
- Morning Market Movers - Benzinga 04.16.12 | 09:04 am
- Top 30 Rallying Small Cap Stocks With Significant Institutional Buying - Seeking Alpha 06.29.11 | 09:06 am
- Company News for April 27, 2011 - Corporate Summary - Zacks 04.27.11 | 10:04 am
- 5 Oncology Drugs Available for Partnering - Seeking Alpha 04.27.11 | 09:04 am
- 7 Diverse U.S. IPOs Test Investor Appetites This Week - Seeking Alpha 02.13.11 | 06:02 am
